Vulvar sweat gland carcinoma
Sweat gland cancer is a relatively rare malignant tumor of the skin appendages, accounting for 2.2% to 8.4% of skin malignant tumors. Most sweat gland tumors are benign tumors. Among the 109 sweat gland tumors reported by Tulenko, sweat gland adenomas accounted for 88% and sweat gland cancers accounted for only 12%. Vulvar sweat gland cancer is very rare, accounting for only 0.5% of vulvar malignant tumors. The age of onset is 30 to 67 years old, and it is more common in women than in men.
-
Site of disease:
vulva -
Infectious :
Not contagious -
Frequent population:
Women aged 30 to 67 -
Related symptoms:
Vulvar swelling purulent discharge subcutaneous nodules capillary dilation bloody exudate -
Concurrent disease:
Related Drugs
Fluorouracil Tablets
Indication: It is the main chemotherapy drug for malignant hydatidiform mole and choriocarcinoma. It is also used for adjuvant chemotherapy and palliative treatment of breast cancer, digestive tract tumors (including primary and metastatic liver cancer and pancreatic cancer), ovarian cancer and primary bronchial lung cancer.
Manufacturer:
GRAND PHARMACEUTICAL(China) Co., Ltd.
Fluorouracil Injection
Indication: This product has a wide anti-tumor spectrum and is mainly used to treat digestive tract tumors or high-dose fluorouracil to treat choriocarcinoma. It is also commonly used to treat breast cancer, ovarian cancer, lung cancer, cervical cancer, bladder cancer and skin cancer.
Manufacturer:
Shanghai JINDI Jiuzhou (Anyang) Pharmaceutical Co., Ltd.
Compound fluorouracil oral solution
Indication: Used for the treatment of digestive tract cancer (colon cancer, rectal cancer, gastric cancer), breast cancer, primary liver cancer and other cancers.
Manufacturer:
BESTWAY Pharmaceutical Co., Ltd.
Imiquimod cream
Indication: Genital and perianal condyloma acuminatum in adults.
Manufacturer:
YANGTZE River Pharmaceutical Group Jiangsu JOINT STOCK Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Harbin Medisan Pharmaceutical Co., Ltd.
Related Ingredients